Faculty Opinions recommendation of Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.

Author(s):  
Howard Fields
2020 ◽  
Author(s):  
Samuel David Clark

AbstractThe kappa opioid receptor (KOR) and its endogenous ligands dynorphins (DYN) have been implicated in the development or symptomatology of a variety of neuropsychiatric disorders. This review covers a brief history of the development of KOR agonists and antagonists, their effects in healthy volunteers, and the potential role of DYN/KOR dysfunction in schizophrenia and major depressive disorder from a translational perspective. The potential role of DYN/KOR dysfunction in schizophrenia is based on several lines of evidence. Selective KOR agonists induce affective states in healthy volunteers with similarities to the symptoms of schizophrenia. Studies have shown increased DYN in patients with schizophrenia, although the data have been mixed. Finally, meta-analytic data have shown that opioid antagonists are associated with reductions in the symptoms of schizophrenia. The potential role of DYN/KOR dysfunction in major depressive disorder is also based on a combination of preclinical and clinical data. Selective KOR agonists have shown pro-depressive effects in human volunteers, while selective KOR antagonists have shown robust efficacy in several preclinical models of antidepressant activity. Small studies have shown that nonselective KOR antagonists may have efficacy in treatment-resistant depression. Additionally, recent clinical data have shown that the KOR may be an effective target for treating anhedonia, a finding relevant to both schizophrenia and depression. Finally, recommendations are provided for translating preclinical models for schizophrenia and major depressive disorder into the clinic.


2015 ◽  
Vol 99 ◽  
pp. 600-609 ◽  
Author(s):  
Jenny Morgenweck ◽  
Kevin J. Frankowski ◽  
Thomas E. Prisinzano ◽  
Jeffrey Aubé ◽  
Laura M. Bohn

2008 ◽  
Vol 22 (S1) ◽  
Author(s):  
Carlyn C Zylstra ◽  
Lisa M Zelinski ◽  
Eunhee Chung ◽  
Yusuke Ohgami ◽  
Donald Y Shirachi ◽  
...  

1992 ◽  
Vol 58 (4) ◽  
pp. 435-442
Author(s):  
Tsutomu Suzuki ◽  
Yoshinao Shiozaki ◽  
Yoshikazu Masukawa ◽  
Miwa Misawa ◽  
Hiroshi Nagase

2019 ◽  
Vol 11 (1) ◽  
pp. 12-20 ◽  
Author(s):  
Mark A. Gillman

Background: Joseph Priestley’s discovery of nitrous oxide (N2O) was recorded in 1772. In the late 1790’s, Humphry Davy experimented with the psychotropic properties of N2O, describing his observations in a book, published in 1800. A dentist, Horace Wells discovered anaesthesia with N2O in 1844. Over a century after Davy, its potential usefulness in psychiatry was first recognised. The seminal researches in neuropsychiatry, between 1920 and 1950, mainly used anaesthetic concentrations of the gas. The psychotropic actions of N2O, at non-anaesthetic doses, were first used by dentists, mainly for its anxiolytic action. In modern dentistry, N2O is always mixed with at least 30% oxygen and titrated to doses rarely exceeding 40% of N2O. At these lower concentrations, untoward effects are almost always avoided, including over-sedation and/or anaesthesia. In the early 1980’s, the low-dose dental titration technique was first used to investigate and treat psychiatric conditions, including substance abuse. Until then, most physicians regarded the gas only as an anaesthetic agent. An exception was obstetricians who used a fixed 50% concentration of N2O diluted with oxygen for analgesia during parturition. In 1994, to clearly distinguish between anaesthetic and non-anaesthetic concentrations (as used in dentistry), the term Psychotropic Analgesic Nitrous oxide (PAN) was introduced. Objective: This paper will give a brief history of the use of the N2O in psychiatry since the psychotropic actions were first recognised in the 18th century until the present. Conclusion: The role of other non- opioid systems, and the extent to which they contribute to the psychotropic properties of N2O, still remains to be established.


Sign in / Sign up

Export Citation Format

Share Document